VR Adviser’s Ambrx Biopharma Inc AMAM Stock Holding History

VR Adviser’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,070,000	Closed	-$29.5M	–	43
2023 Q4	$29.5M	Hold	2,070,000	–	–	2.02%	13
2023 Q3	$23.8M	Sell	2,070,000 -414,960	-17%	-$5.65M	2.51%	16
2023 Q2	$40.9M	Sell	2,484,960 -813,617	-25%	-$10.2M	6.54%	7
2023 Q1	$29.4M	Buy	+3,298,577	New	+$16.6M	5.74%	6

VR Adviser's AMAM Position: Q1 2024 in Review

VR Adviser sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 2,070,000 shares — an estimated $29.5M sold.

VR Adviser first reported a position in AMAM in Q1 2023 and held it in 4 quarters. The position peaked at $40.9M in Q2 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

VR Adviser reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
VR Adviser sold 2,070,000 Ambrx Biopharma Inc shares in Q1 2024, an estimated $29.5M.
VR Adviser first reported a position in Ambrx Biopharma Inc in Q1 2023 and held it in 4 quarters.
VR Adviser's Ambrx Biopharma Inc position peaked at $40.9M in Q2 2023.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on VR Adviser's 13F filing for Q1 2024, filed 15 May 2024.